Trial Profile
A Multicentre, Randomised Controlled Trial of Exenatide Versus Standard Care in Acute Ischemic Stroke (TEXAIS)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Dec 2023
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Stroke
- Focus Therapeutic Use
- Acronyms TEXAIS
- 29 Nov 2023 Status changed from recruiting to discontinued, as per Results published in the Stroke
- 29 Nov 2023 Results published in the Stroke
- 29 Nov 2023 Primary endpoint has not been met. (improved neurological outcome), as per Results published in the Stroke